細胞、基因治療製造服務市場:規模,佔有率,趨勢分析:各類型,各適應症,各用途,各終端用戶,各地區展望,競爭策略,至2030年的各市場區隔預測
市場調查報告書
商品編碼
1089963

細胞、基因治療製造服務市場:規模,佔有率,趨勢分析:各類型,各適應症,各用途,各終端用戶,各地區展望,競爭策略,至2030年的各市場區隔預測

Cell & Gene Therapy Manufacturing Services Market Size, Share & Trends Analysis By Type, By Indication, By Application, By End-user, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 245 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

細胞、基因治療製造服務的市場規模,預計今後以11.6%的年複合成長率擴大,至2030年達到206億8,000萬美元。製藥公司和CDMO的合作,癌症和各種標的疾病的盛行率上升,醫藥品的研究開發增加,CDMO對尖端技術的高投資,這些要素成為推動市場要素。

本報告提供全球細胞、基因治療製造服務市場相關調查,市場概要,以及各類型,各適應症,各用途,各終端用戶,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 成長要素,阻礙因素,機會,課題的分析
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • COVID-19細胞、基因治療製造服務市場的影響

第5章 市場變數及預測

  • SWOT分析
  • PESTEL分析
  • 波特的五力分析
  • 熱圖分析

第6章 全球細胞、基因治療製造服務市場,各類型,2019年~2030年(100萬美元)

  • 細胞治療
    • 同種異體
    • 自體
    • 病毒載體
  • 基因治療
    • 非病毒載體
    • 寡核苷酸
    • 病毒載體

第7章 全球細胞、基因治療製造服務市場,各適應症,2019年~2030年(100萬美元)

  • 心血管疾病
  • 中樞神經系統障礙
  • 感染疾病
  • 腫瘤系疾病
  • 眼科疾病
  • 整形外科疾病
  • 其他

第8章 全球細胞、基因治療製造服務市場,各用途,2019年~2030年(100萬美元)

  • 臨床製造
  • 商業製造

第9章 全球細胞、基因治療製造服務市場,各終端用戶,2019年~2030年(100萬美元)

  • 學術研究
  • 其他
  • 製藥公司、生物科技企業

第10章 全球細胞、基因治療製造服務市場,各地區,2019年~2030年(100萬美元)

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第11章 企業簡介

  • ABL, Inc
  • Andelyn Biosciences
  • Anemocyte Srl
  • BioCentriq
  • Catalent, Inc
  • Cell and Gene Therapy Catapult
  • Charles River Laboratories
  • Commercializing Living Therapies
  • ElevateBio
  • F. Hoffmann-La Roche Ltd.
  • FinVector
  • FUJIFILM Holdings Corporation
  • JRS PHARMA
  • Lonza
  • Merck KGaA
  • NIKON CORPORATION
  • Oxford Biomedica plc
  • Porton Biopharma Limited
  • Resilience
  • RoslinCT
  • Takara Bio Inc
  • The Discovery Labs LLC
  • Thermo Fisher Scientific, Inc
  • Vibalogics
  • WuXi AppTec
簡介目錄
Product Code: BIOT2229

Global Cell & Gene Therapy Manufacturing Services Market projected to be worth USD 20.68 billion by 2030.

According to SPER Market Research, the Cell & Gene Therapy Manufacturing Services Market estimated to reach USD 20.68 billion by 2030 with a CAGR of 11.6%. The collaboration between pharmaceutical companies and CDMOs, rising prevalence of cancer and various targeted disease, rising pharmaceutical research & development, High investments by CDMOs in advanced technology; these factors act as the fuel to the escalation of the market.

Impact of COVID-19 on the Cell & Gene Therapy Manufacturing Services Market

Because of the outbreak of COVID-19, there is disruption of clinical trials due to the deferral of patient enrolment. Clinical trials such as; cardiovascular disease, respiratory disease, oncology, anti-infective, were the worst-hit in this time. This leads to the squeeze of production and research.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030
  • Segments covered: By Product, By Region
  • Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa
  • Companies Covered: ABL Inc., Andelyn Biosciences, Anemocyte Srl, BioCentriq, Catalent, Inc., Cell and Gene Therapy Catapult, Charles River Laboratories, Commercializing Living Therapies, ElevateBio, F. Hoffmann-La Roche Ltd., FinVector, FUJIFILM Holdings Corporation, JRS PHARMA, Lonza, Merck KGaA, NIKON CORPORATION, Oxford Biomedica plc, Porton Biopharma Limited, Resilience, RoslinCT, Takara Bio Inc., The Discovery Labs LLC, Thermo Fisher Scientific, Inc., Vibalogics, WuXi AppTec

Driver: rising investments in pharmaceutical Research & Development

The key drivers to the escalation of the market are; towering prevalence of cancer and other target diseases, rising investments in pharmaceutical research & development, funding in advanced technologies by CDMOs, escalating partnerships and agreements among CDMOs and pharmaceutical companies.

Restraint: High running costs coupled with cell & gene therapy manufacturing

The manufacturing of cell & gene therapy is costly; this might resist the expansion of market.

Opportunity: growing figure of cell & gene therapy clinical trials

The demand for cell & gene therapies is escalating globally, the elevated number of cell & gene therapy clinical trials; give the impetus to the top player in this market.

Challenges:

There is chances of superfluous outcomes and threat of mutagenesis; are the challenges to this market.

Global Cell & Gene Therapy Manufacturing Services Market, By Type:

Based on the Type, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Cell Therapy {Allogeneic (Hematopoietic Stem Cells, Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, Natural Killer Cells, Other Allogeneic Cells, T-cells), Autologous (Hematopoietic Stem Cells, Mesenchymal Stem Cells, Natural Killer Cells, T-cells), Viral Vector (Adeno-associated Virus Vectors, Other Viral Vectors, Retroviral Vectors)}, Gene Therapy {Non-viral Vector, Oligonucleotides, Viral Vector (Retroviral Vectors, Adeno-associated Virus Vectors, Other Viral Vectors)}.

Global Cell & Gene Therapy Manufacturing Services Market, By Indication:

Based on the Indication, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases, Oncology Diseases, Ophthalmology Diseases, Orthopaedic Diseases, Other Indications

Global Cell & Gene Therapy Manufacturing Services Market, By Application:

Based on the Application, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Clinical Manufacturing, Commercial Manufacturing.

Global Cell & Gene Therapy Manufacturing Services Market, By End User:

Based on the End-Users, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Other End Users.

Global Cell & Gene Therapy Manufacturing Services Market, By Region:

North America owns the prime share of this market; this is due to the increasing prevalence of cancer, increasing research in stem cell and cancer in this region.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Cell & Gene Therapy Manufacturing Services Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Cell & Gene Therapy Manufacturing Services Market, By Type, 2019-2030 (USD Million)

  • 6.1. Cell Therapy
    • 6.1.1. Allogeneic
      • 6.1.1.1. Hematopoietic Stem Cells
      • 6.1.1.2. Induced Pluripotent Stem Cells
      • 6.1.1.3. Mesenchymal Stem Cells
      • 6.1.1.4. Natural Killer Cells
      • 6.1.1.5. Other Allogeneic Cells
      • 6.1.1.6. T-cells
    • 6.1.2. Autologous
      • 6.1.2.1. Hematopoietic Stem Cells
      • 6.1.2.2. Mesenchymal Stem Cells
      • 6.1.2.3. Natural Killer Cells
      • 6.1.2.4. T-cells
    • 6.1.3. Viral Vector
      • 6.1.3.1. Adeno-associated Virus Vectors
      • 6.1.3.2. Other Viral Vectors
      • 6.1.3.3. Retroviral Vectors
  • 6.2. Gene Therapy
    • 6.2.1. Non-viral Vector
    • 6.2.2. Oligonucleotides
      • 6.2.2.1. Other Non-viral Vectors
    • 6.2.3. Viral Vector
      • 6.2.3.1. Retroviral Vectors
      • 6.2.3.2. Adeno-associated Virus Vectors
      • 6.2.3.3. Other Viral Vectors

7. Global Cell & Gene Therapy Manufacturing Services Market, By Indication, 2019-2030 (USD Million)

  • 7.1. Cardiovascular Diseases
  • 7.2. Central Nervous System Disorders
  • 7.3. Infectious Diseases
  • 7.4. Oncology Diseases
  • 7.5. Ophthalmology Diseases
  • 7.6. Orthopedic Diseases
  • 7.7. Other Indications

8. Global Cell & Gene Therapy Manufacturing Services Market, By Application, 2019-2030 (USD Million)

  • 8.1. Clinical Manufacturing
  • 8.2. Commercial Manufacturing

9. Global Cell & Gene Therapy Manufacturing Services Market, By End User, 2019-2030 (USD Million)

  • 9.1. Academic & Research Institutes
  • 9.2. Other End Users
  • 9.3. Pharmaceutical & Biotechnology Companies

10. Global Cell & Gene Therapy Manufacturing Services Market, By Region, 2019-2030 (USD Million)

  • 10.1. North America
    • 10.1.1. United States
    • 10.1.2. Canada
    • 10.1.3. Mexico
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. South America
    • 10.4.1. Brazil
    • 10.4.2. Argentina
    • 10.4.3. Rest of South America
  • 10.5. Middle East & Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

  • 11.1. ABL, Inc.
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. Andelyn Biosciences
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. Anemocyte Srl
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. BioCentriq
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Catalent, Inc.
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Cell and Gene Therapy Catapult
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Charles River Laboratories
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Commercializing Living Therapies
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. ElevateBio
    • 11.9.1. Company details
    • 11.9.2. Financial outlook
    • 11.9.3. Product summary
    • 11.9.4. Recent developments
  • 11.10. F. Hoffmann-La Roche Ltd.
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. FinVector
    • 11.11.1. Company details
    • 11.11.2. Financial outlook
    • 11.11.3. Product summary
    • 11.11.4. Recent developments
  • 11.12. FUJIFILM Holdings Corporation
    • 11.12.1. Company details
    • 11.12.2. Financial outlook
    • 11.12.3. Product summary
    • 11.12.4. Recent developments
  • 11.13. JRS PHARMA
    • 11.13.1. Company details
    • 11.13.2. Financial outlook
    • 11.13.3. Product summary
    • 11.13.4. Recent developments
  • 11.14. Lonza
    • 11.14.1. Company details
    • 11.14.2. Financial outlook
    • 11.14.3. Product summary
    • 11.14.4. Recent developments
  • 11.15. Merck KGaA
    • 11.15.1. Company details
    • 11.15.2. Financial outlook
    • 11.15.3. Product summary
    • 11.15.4. Recent developments
  • 11.16. NIKON CORPORATION
    • 11.16.1. Company details
    • 11.16.2. Financial outlook
    • 11.16.3. Product summary
    • 11.16.4. Recent developments
  • 11.17. Oxford Biomedica plc
    • 11.17.1 Company details
    • 11.17.2 Financial outlook
    • 11.17.3 Product summary
    • 11.17.4 Recent developments
  • 11.18. Porton Biopharma Limited
    • 11.18.1. Company details
    • 11.18.2. Financial outlook
    • 11.18.3. Product summary
    • 11.18.4. Recent developments
  • 11.19. Resilience
    • 11.19.1. Company details
    • 11.19.2. Financial outlook
    • 11.19.3. Product summary
    • 11.19.4. Recent developments
  • 11.20. RoslinCT
    • 11.20.1. Company details
    • 11.20.2. Financial outlook
    • 11.20.3. Product summary
    • 11.20.4. Recent developments
  • 11.21. Takara Bio Inc.
    • 11.21.1. Company details
    • 11.21.2. Financial outlook
    • 11.21.3. Product summary
    • 11.21.4. Recent developments
  • 11.22. The Discovery Labs LLC
    • 11.22.1. Company details
    • 11.22.2. Financial outlook
    • 11.22.3. Product summary
    • 11.22.4. Recent developments
  • 11.23. Thermo Fisher Scientific, Inc.
    • 11.23.1. Company details
    • 11.23.2. Financial outlook
    • 11.23.3. Product summary
    • 11.23.4. Recent developments
  • 11.24. Vibalogics
    • 11.24.1. Company details
    • 11.24.2. Financial outlook
    • 11.24.3. Product summary
    • 11.24.4. Recent developments
  • 11.25. WuXi AppTec
    • 11.25.1 Company details
    • 11.25.2 Financial outlook
    • 11.25.3 Product summary
    • 11.25.4 Recent developments

10. Global Cell & Gene Therapy Manufacturing Services Market, By Region, 2019-2030 (USD Million)

  • 10.1. North America
    • 10.1.1. United States
    • 10.1.2. Canada
    • 10.1.3. Mexico
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. South America
    • 10.4.1. Brazil
    • 10.4.2. Argentina
    • 10.4.3. Rest of South America
  • 10.5. Middle East & Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

  • 11.1. ABL, Inc.
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. Andelyn Biosciences
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. Anemocyte Srl
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. BioCentriq
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Catalent, Inc.
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Cell and Gene Therapy Catapult
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Charles River Laboratories
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Commercializing Living Therapies
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. ElevateBio
    • 11.9.1. Company details
    • 11.9.2. Financial outlook
    • 11.9.3. Product summary
    • 11.9.4. Recent developments
  • 11.10. F. Hoffmann-La Roche Ltd.
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. FinVector
    • 11.11.1. Company details
    • 11.11.2. Financial outlook
    • 11.11.3. Product summary
    • 11.11.4. Recent developments
  • 11.12. FUJIFILM Holdings Corporation
    • 11.12.1. Company details
    • 11.12.2. Financial outlook
    • 11.12.3. Product summary
    • 11.12.4. Recent developments
  • 11.13. JRS PHARMA
    • 11.13.1. Company details
    • 11.13.2. Financial outlook
    • 11.13.3. Product summary
    • 11.13.4. Recent developments
  • 11.14. Lonza
    • 11.14.1. Company details
    • 11.14.2. Financial outlook
    • 11.14.3. Product summary
    • 11.14.4. Recent developments
  • 11.15. Merck KGaA
    • 11.15.1. Company details
    • 11.15.2. Financial outlook
    • 11.15.3. Product summary
    • 11.15.4. Recent developments
  • 11.16. NIKON CORPORATION
    • 11.16.1. Company details
    • 11.16.2. Financial outlook
    • 11.16.3. Product summary
    • 11.16.4. Recent developments
  • 11.17. Oxford Biomedica plc
    • 11.17.1 Company details
    • 11.17.2 Financial outlook
    • 11.17.3 Product summary
    • 11.17.4 Recent developments
  • 11.18. Porton Biopharma Limited
    • 11.18.1. Company details
    • 11.18.2. Financial outlook
    • 11.18.3. Product summary
    • 11.18.4. Recent developments
  • 11.19. Resilience
    • 11.19.1. Company details
    • 11.19.2. Financial outlook
    • 11.19.3. Product summary
    • 11.19.4. Recent developments
  • 11.20. RoslinCT
    • 11.20.1. Company details
    • 11.20.2. Financial outlook
    • 11.20.3. Product summary
    • 11.20.4. Recent developments
  • 11.21. Takara Bio Inc.
    • 11.21.1. Company details
    • 11.21.2. Financial outlook
    • 11.21.3. Product summary
    • 11.21.4. Recent developments
  • 11.22. The Discovery Labs LLC
    • 11.22.1. Company details
    • 11.22.2. Financial outlook
    • 11.22.3. Product summary
    • 11.22.4. Recent developments
  • 11.23. Thermo Fisher Scientific, Inc.
    • 11.23.1. Company details
    • 11.23.2. Financial outlook
    • 11.23.3. Product summary
    • 11.23.4. Recent developments
  • 11.24. Vibalogics
    • 11.24.1. Company details
    • 11.24.2. Financial outlook
    • 11.24.3. Product summary
    • 11.24.4. Recent developments
  • 11.25. WuXi AppTec
    • 11.25.1 Company details
    • 11.25.2 Financial outlook
    • 11.25.3 Product summary
    • 11.25.4 Recent developments